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Autocrine growth factors produced by epithelial cells me-
diate the development and proliferation of neoplastic hu-
man prostate tissue. Various approaches have been used 
to down-regulate neoplastic growth of prostate cancer 
using natural flavonoids, soluble receptors, pseudo-lig-
ands, monoclonal antibodies and tyrosine kinase inhibi-
tors (tyrphostins). Selected growth factor/growth factor 
receptor loops (mainly TGFα/EGFR and IGFs/IGFIR) have 
been proposed as regulators of prostate cancer cell 
growth. We have previously determined that blockade 
of IGFIR or VEGF2R signaling pathways by tyrphostin 
AG1024 and SU1498 inhibits autocrine growth and vi-
ability of DU145 cells in vitro. Recently, we compared 
the activity of AG1024 and SU1498 with the inhibiting 
effect of tyrphostin A23 (a selective inhibitor of EGFR). 
The results described in this paper confirm that DU145 
cells do not produce IGFI or EGF. In contrast, DU145 
cells produce a great amount of VEGF, much more than 
TGFα (about 60-fold), and VEGF may be the real auto-
crine growth factor of the investigated cells. The results 
indicate that the growth of DU145 may be regulated by 
at least three autocrine loops: TGFα/EGFR, IGFII/IGFIR 
and VEGF/VEGFR2. Neither AG1024 nor SU1498 affected 
the production of TGFα substantially, which excludes 
the possibility that IGFRs or VEGFR2 inhibitors arrest 
the growth of these cells by inhibition of synthesis and/
or secretion of TGFα. The obtained data indicate that all 
tree investigated tyrphostins (AG1024, SU1498 and A23) 
inhibit signal transmission by Akt (PKB), ERK(1/2), Src 
and STAT in a similar manner. A comparison of the ef-
fects of the investigated tyrphostins indicates that TGFα, 
IGFII and VEGF stimulate cell growth by affecting the 
same signaling pathway. The hypothesis was confirmed 
by the effect of the investigated tyrphostins on activa-
tion of EGFR. All these inhibitors decreased phosphoryla-
tion of EGFR to the same extent, and after the same time 
of incubation with cell culture. These results strongly 
suggest that stimulation of EGFR kinase is the main step 
in the initiation of mitogen signaling in DU145 cells, re-
gardless of the type of ligand (TGFα, IGFs or VEGF) and 
their specific receptors. 
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INTRODUCTION
An important event in the development of the neo-
plastic phenotype is the induction of genes encoding 
growth factors and their receptor (Sporn & Roberts, 
1985; Goustin et al., 1986). The autocrine growth factor-
mediated pathways are engaged in proliferation of hu-
man prostate cancer cells, including the DU145 cell line 
(Marker et al., 2003; Bellezza et al., 2006). Understand-
ing the role of different growth factors in the control of 
autocrine growth may help to clarify the mechanism of 
prostate cancer progression.
The growth of human prostate cancer cells is prob-
ably dependent on several growth factors. Members of 
the EGF, IGF, PDGF, VEGF and FGF families and 
neurotrophins have been postulated as stimulators of 
prostate cell growth (Ferrer et al., 1999; Ozen et al., 2001; 
Montano & Djamgoz, 2004; Bellezza et al., 2006; Gen-
nigens et al., 2006). Selected growth factor/growth fac-
tor receptor loops such as EGF/EGFRs, IGFs/IGFRs 
and FGFs/FGFRs are probably engaged in the autocrine 
growth regulation of prostate cancer cell lines (Ozen et 
al., 2001; Bellezza et al., 2006; Gennigens et al., 2006). 
An increased production of transforming growth factor 
α (TGFα), ligand from EGF family,  has been found 
in several prostate cell lines, including DU145 and syn-
thetic inhibitors of EGFR have been shown to decrease 
the proliferation of different prostate cell lines (Vicen-
tini et al., 2003; Bonaccorsi et al., 2004; Sgambato et al., 
2004). On the other hand, acquired resistance to inhibitors 
of EGFR has been reported clinically (Jimeno & Hidalgo, 
2005) and suggested to be associated with increased sig-
naling through the IGFI receptor (Jones et al., 2004). A 
high level of IGFs and VEGF has also been observed in 
patients with prostate cancer (Ferrer et al., 1999; Genni-
gens et al., 2006) suggesting their participation in autocrine 
growth regulation of the investigated cells. It has been 
proposed, that IGFs affect the growth of prostate cells via 
the EGF receptor and VEGF is a mediator of their motil-
ity and an angiogenic factor (Jackson et al., 2002). In con-
trast to EGF, IGF and VEGF, the production of NGF 
is progressively lost in prostate cancer development (Mon-
tano & Djamgoz, 2004) and exogenous NGF inhibits the 
growth of DU145 cells (Sigala et al., 2008).
The mechanism of autocrine growth regulation of 
prostate cells is far from being explained. Why does one 
type of cancer cells produce increased levels of several 
growth factors and do they activate the same or differ-
ent signaling pathways?. Investigation of the molecular 
mechanisms of interaction between different autocrine 
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signal pathways may explain the mechanism of neoplas-
tic growth and resistance of cancer cells to single inhibi-
tors (cytostatics), often observed in anticancer therapy.
A useful tool for use in the investigation of autocrine 
cell growth regulation are inhibitors of tyrosine kinas-
es (Bennasroune et al., 2004; Madhusudan & Ganesan, 
2004; Lacal, 2006), including small-molecular compounds 
known as tyrphostins (tyrosine kinase inhibitors) (Lev-
itzki & Gazit, 1995). Previous experiments indicated 
that tyrphostins: AG1024 and SU1498 inhibit autocrine 
growth of DU145 human prostate cancer cells in a dose-
dependent manner (Kisielewska et al., 2008). In this pa-
per, we compare the mitogenic signal transmission ini-
tiated by different autocrine growth factor receptors of 
DU145 cells: EGFR, IGFIR and VEGFR2.
MATERIALS AND METHODS
Chemicals and reagents. Dulbecco’s Modified Ea-
gle’s Medium/Nutrient F-12 Ham (DMEM/F12), Mini-
mal Essential Medium (MEM), bovine serum albumin 
(BSA), transferrin, sodium selenite (Na2SeO3), Hoechst 
33258, propidium iodide, MTT (thiazolyl blue tetrazo-
lium bromide), dimethylsulfoxide (DMSO) and tyrosine 
kinase inhibitors: A23 (EGFR IC50 = 35 µM), AG1024 
(IGFIR IC50 = 0.4 µM) and SU1498 (VEGFR2 IC50 = 0.7 
µM) were purchased from Sigma (St. Louis, MO, USA). 
Fetal bovine serum (FBS) was obtained from PAA Lab-
oratories GmbH (Austria). RNeasy® Mini Kit was pur-
chased from QIAGEN (Germany). RayBio® Human 
EGF (TGFα, VEGF, IGFI) ELISA kits were bought 
from RayBiotech, Inc. (USA). Oligo GEArray® Human 
Cancer Pathway Finder™ and CASE™ (Cellular Activa-
tion of Signaling ELISA) kits for EGFR, Akt, ERK1/2, 
Src and STAT3 were obtained from SuperArray Bio-
science Corporation (USA). X-Ray film was obtained 
from Agfa (Belgium). Other reagents were provided by 
POCh (Gliwice, Poland).
Stock solutions of the tyrphostins were prepared by 
dissolving the compounds in DMSO to the final con-
centration of 10 mM or 100 mM in the case of A23 
and storing the resultant solutions at –20 ºC. DMEM/
F12 (1 : 1) medium was used do dilute stock solutions to 
working concentrations (1–10 µM).
Cell culture. DU145 (HTB-81) cells were obtained 
from the American Type Culture Collection (ATCC) and 
cultured in MEM in the presence of 10 % FBS. The cells 
were passaged two times per week. The experiments 
were carried out in DMEM/F12 supplemented with 
BSA (0.5 mg/ml), transferrin (5 μg/ml) and Na2SeO3 
(2 ng/ml).
Proliferation of the investigated cells was determined 
by the procedure described earlier (Kisielewska et al., 
2008). The mean ± S.E.M. of at least three experiments 
with ten replicates each was used. Statistical analysis was 
performed with the use of the Statistica 9 program.
Cell cycle analysis. To estimate the proportion of 
cells in various phases of the cell cycle, cellular DNA 
contents was measured by flow cytometry (FACS Scan 
from Beckton-Dickinson) as described earlier (Kisielews-
ka et al., 2008). The resultant data were analyzed with 
FCS Express V3 with Multicycle plug-in.
Cellular activation of signalling ELISA (CASE). 
Cells (1 × 104) were seeded in 96-well plates and cultured 
in DMEM containing 10 % FBS for one day, followed 
with a period of serum-deprivation of 24 h (in DMEM/
F12+), then cultured for 3 to 24 h in DMEM/F12+ 
supplemented with the investigated tyrphostins (at re-
spective IC50 concentrations). Next the cells were fixed 
(4 % formaldehyde) and stained with, phospho-protein 
or pan-protein primary antibodies (12 h at 4 °C). Sub-
sequently, the cells were washed, stained with secondary 
antibody (60 min at room temperature), incubated with 
color developer (3–5 minutes at room temp.), and the 
plates were read at 450 nm. Thereafter, the plates were 
washed thrice with PBS and then stained with crystal vi-
olet. The absorbance was measured using a Tecan (Spec-
tra Fluor Plus) multiscan plate reader.
Readings were taken to assess the total number of 
cells per well. The results were calculated as the ratio of 
450 nm absorbance (antibody signal) and 595 nm ab-
sorbance (cell number), and normalized to non-stimulat-
ed cells.
RNA isolation. Total RNA was isolated from DU145 
cells (up to 6 × 106 cells) using RNeasy Mini Kit (Qiagen, 
Hilden, Germany), dissolved in 30 µl of RNase-free wa-
ter and stored at –20 °C. The integrity of ribosomal RNA 
and DNA contamination was checked using denaturing 
formaldehyde gel electrophoresis (l %) before proceeding 
with the microarray analysis. Protein and phenol contamina-
tion and concentration of total RNA was assessed by deter-
mining the ratio A260/280 and A260/230 ,  respectively (NanoDrop).
Microarray analysis. Superarray® hybridization was 
performed on 128 sites (2 blanks, 4 negative reference spots, 
2 biotinylated artificial sequences, 6 household gene spots, 
and 113 human genes related to drug metabolism) on 
cDNA gene microarrays (Oligo GEArray® Human Can-
cer Pathway Finder™ OHS-033, SuperArray® Bioscience 
Corporation; Frederick, MD, USA). Four arrays were used to 
determine the difference in mRNA expression between cells 
treated with the three different receptor tyrosine kinase in-
hibitors (A23 80 μM and SU1498 10 μM and AG1024 10 
μM) and untreated cells.
DU145 cells were investigated after 24 h of serum starva-
tion followed by 30 h incubation with or without (control) 
the investigated compounds.
Work-up of the array was performed according to the 
manufacturer’s protocol. Single-stranded cDNA was syn-
thesized (from approx. 6 μg of total RNA) and labeled 
with dUTP-biotin by using the TrueLabellingAMP™ 
2.0 kit. The nylon membrane based DNA macroar-
ray was hybridized overnight at 60 °C with the biotin-
labelled cDNA. The hybridized membrane was subjected 
to chemiluminesence detection with streptavidin-linked al-
kaline phosphatase and CDPstar substrate. The resulting 
signals were captured on X-ray film and analyzed with 
the TIGR Spotfinder 3.1.1 program (Saeed et al., 2003). 
The assessed luminescence intensities were elaborated 
with the use of MIDAS program. Lowess smoothing 
and standard deviation regularization were applied to raw 
data (Quackenbush, 2002; Pasanen et al., 2003; Saeed et 
al., 2003). 
The differences in mRNA levels for the investigated 
genes, between the control cells and tyrphostins-treated 
cells were expressed as log2(T/C); where T is lumines-
cence intensity of a spot on an array hybridized with 
cDNA obtained from tyrphostin-treated cells, and C — 
from untreated cells.
Quantitation of selected growth factors in cell 
culture medium. DU145 cells were seeded on 24-well 
plates, 8 × 104 cells per well in MEM, SP, NEAA and 
10 % FBS. After 24 h, the cells were serum-starved for 
24 h in DMEM/F12+. Afterwards, the medium was re-
placed by a fresh dose of DMEM/F12+ supplemented 
or not with A23 (80 µM), AG1024 (8 µM), SU1498 (8 
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µM), and the cells were incubated for additional 24 h or 
48 h. Subsequently, samples of culture media were col-
lected and analyzed for the presence of the investigated 
growth factors with the use of RayBio Human EGF, 
TGFα, VEGF and IGF-I ELISA Kits following 
manufacturer’s instruction with minor modifica-
tions. At the same time, the number of DU145 
cells was estimated in each well. Conditioned 
media from cell cultures and standard solutions 
were incubated on ELISA plates overnight at 
4 °C. Biotin-labeled secondary antibodies were 
applied for 3 h in room temp. HRP-Streptavi-
din was added to the plates for 45 min. Finally, 
TMB One-Step Substrate Reagent was added to 
each well and incubated in the dark with gentle 
shaking for 30 min.
Standard curve (exponential model) was fit-
ted to obtained data and the concentration of 
the secreted growth factors in culture medium 
was calculated. The results were expressed as 
pg or ng of the investigated protein produced 
by 1 × 106 cells after 24 h of incubation. The 
effects of tyrosine kinases inhibitors were 
shown as the ratio of the amount of growth 
factors produced by the treated cells to the 
amount produced by the control cells.
RESULTS
The recently reported results on the cyto-
static effects of AG1024 and SU1498 on au-
tocrine growth of DU145 cells (Kisielewska et 
al., 2008) indicated similar inhibitory activities 
of the both investigated tyrpostins. The next 
step in our investigations was a comparison 
of cytostatic activity of AG1024 and SU1498 
with the effect of a selective inhibitor of epidermal 
growth factor receptor (EGFR) — tyrphostin A23. 
The anti-proliferative activity of the investigated tyr-
phostins was determined by two color-
imetric methods (MTT and CV). The 
influence of the tyrphostins on auto-
crine growth of DU145 cells was char-
acterized by average values estimated 
by both methods. Tyrphostins A23, 
AG1024 and SU1498 inhibited growth 
of DU145 cells by 50 % at the concen-
tration: 35 μM, 3.2 μM  and 3.6 μM 
respectively.
These results indicate that only 
EGFR-induced signaling is inhibited by 
the specific tyrphostin (A23) in the same 
concentration range as the inhibition of 
the enzymatic activity of the kinase re-
ceptor (IC50 = 35 μM) and receptor auto-
phosphorylation (IC50 = 40 μM). Effective 
cell growth inhibition by the other two 
investigated tyrphostins required much 
higher concentration of the compounds 
than those needed to inhibit the enzy-
matic activity of IGFIR and VEGFR2. 
However, to observe an inhibitory effect 
of the tyrphostin AG1024 (the effect of 
SU1498 was not determined) on the au-
tophosphorylation of specific receptor 
(IC50 = 7 μM) required a similar concen-
tration range as for cell proliferation of 
DU145 cells. It should be noted that the 
growth inhibition of DU145 cells by all 
the investigated tyrphostins was revers-
ible (not shown). 
Table 1. Percentage of DU145 cells in different cell cycle phases after in-
cubation with tyrphostins
AG1024, SU1498 and A23 were added at concentration equal their respec-
tive IC50 and 2 × IC50 in serum-free DMEM/F12+ for 30 and 48 h.
30 h
Cycle phase
Apoptosis G1/G2
G1&G0 S G2&M
%
 o
f c
el
ls
Control 57.0 25.5 17.5 – 3.26
AG1024 IC50 71.4 15.8 12.8 – 5.58
AG1024 10 µM 68.9 18.6 12.5 – 5.52
SU1498 IC50 74.1 10.6 15.3 – 4.85
SU1498 10 µM 68.4 16.7 14.9 – 4.59
A23 IC50 59.7 19.1 11.7 8.3 5.09
A23 80 µM 56.1 24.4 9.8 8.7 5.74
48 h
Cycle phase
Apoptosis G1/G2
G1&G0 S G2&M
%
 o
f c
el
ls
Control 60.8 21.7 17.5 – 3.47
AG1024 IC50 72.6 14.6 12.8 – 5.68
AG1024 10 µM 70.8 16.7 12.5 – 5.67
SU1498 IC50 72.2 9.7 11.8 3.7 6.12
SU1498 10 µM 67.03 14.64 12.51 4.96 5.36
A23 IC50 52.8 22.5 10.8 13.0 4.89
A23 80 µM 46.1 22.4 7.8 22.8 5.88
Figure 1. Concentration of growth factors in DU145 cell culture medium
Mean by ELISA method for cell culture medium after 24 h (C, D) or 24 h and 48 h 
(A, B) of incubation, compared to mean values of absorbance for dilution buffer 
and two standard samples with lowest concentrations of EGF (A) and IGF-I (B) or 
three standard samples for TGFα (C) and VEGF (D). Differences between samples 
was assessed by Mann-Withney U-test (*p < 0.05, **p < 0.001, ns, not significant).
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Influence of tyrphostins AG1024, SU1498 and A23 on 
DU145 cell cycle
The effect of tyrphostins AG1024 and SU1498 on the 
cell cycle was described earlier (Kisielewska et al., 2008). 
They influenced the cell cycle of DU145 in a similar 
manner. They increased the cell number in G1 and S 
phases and decreased it in G2 phase in comparison with 
the control culture. AG1024 did not stimulate apopto-
sis, and the cytotoxic effect of SU1498 was very weak. 
In this paper, we compare the influence of AG1024 and 
SU1498 with the inhibitor of EGF receptor (A23) on 
the cell cycle of DU145 cells (tested in the same experi-
ment). In contrast to tyrphostins AG1024 and SU1498, 
inhibition of EGF receptor by tyrphostin A23 was as-
sociated with a significantly increased proportion of ap-
optotic cells (Table 1). 
Synthesis of autocrine growth factors
The effect of the investigated tyrphostins on growth 
and cell cycle of DU145 cells suggests one of the two 
possibilities: a) each of the inhibitors stimulates a separate 
signaling pathway or b) two or tree investigated inhibi-
tors utilize a common pathway of mitogen signaling. The 
results shown in Fig. 1 indicate that DU145 cultured in 
DMEM/F12+ produce vascular endothelial growth fac-
tor (VEGF) and TGFα and confirm that the cells do not 
produce EGF and IGFI. Moreover, the amount of VEGF 
secreted to the culture medium calculated per 106 cells, 
was about 60 times higher (6.35 ± 1.05 ng/24 h) than the 
amount of TGFα (118.4 ± 3.3 pg/24 h). The prostate can-
cer cell line DU145 did not secrete a detectable amount 
of EGF or IGF-I, even after 48 h of incubation.
Comparison of the effect of tyrphostins AG1024, 
SU1498 and A23 on gene expression and 
phosphorylation of selected signaling proteins
To compare the signaling pathways of IGFIR, VEG-
FR2 and EGFR, we tested the effect of the investigated 
inhibitors on the expression of selected genes and on 
phosphorylation of some proteins engaged in mitogen 
stimulated signaling pathways.
The effect of the investigated tyrphostins on gene ex-
pression was assessed by cDNA microarray analysis, us-
ing Oligo GEArray® Human Cancer Pathway Finder™ 
OHS-033. Four arrays were used to determine differences 
in mRNA expression between DU145 cells treated with 
A23, SU1498, and AG1024 (at the concentration equal to 
2 × IC50) and untreated cells after 24 h serum starvation 
followed by 30 h incubation with or without (control) the 
investigated compounds. The effect of the inhibitors on 
the expression of selected genes related to six different 
signaling pathways is shown in Fig. 2. Differences (mainly 
between AG1024 and A23) were observed in the response 
of genes engaged in regulation of the cell cycle and cell 
adhesion. The former could have re-
sulted, at least partly, from the abil-
ity of the investigated tyrphostins to 
stimulate apoptosis. Only A23 (at 
the concentration equal to its IC50) 
does effectively stimulate this proc-
ess (8.3 % of apoptotic cells) after 30 
h of incubation. The different effects 
on expression of genes engaged in 
cell adhesion may be characteristic 
for individual signaling pathways af-
fected by these tyrphostins. In the 
remaining cellular processes, the dif-
ferences in the levels of gene expres-
sion in response to individual inhibi-
tors were much smaller. 
Stimulation of EGFR receptor 
may trigger numerous intracellular 
signaling pathways involved in such 
processes as: survival (Akt/PKB), 
cell growth (ERK1/2; Src) and 
transcription (STAT). The activ-
ity of these proteins is regulated by 
phosphorylation/dephosphorylation. 
A comparison of the effects of the 
inhibitors of the EGFR, IGFIR 
and VEGFR2 tyrosine kinases on 
phosphorylation of the investigated 
proteins is shown in Fig. 3. The 
obtained results indicate a similar-
Figure 2. Influence of investigated tyrphostins on expression of 
genes engaged in different cellular processes
Proportion of up- or down-regulated to total analyzed genes in-
volved in particular cell signalling pathways. DU145 cells were in-
cubated for 30 h with AG1024, SU1498 and A23 added at concen-
tration equal their IC50.
Figure 3. Effect of tyrphostins AG1024, SU1498 and A23 on phosphorylation of Akt (A), 
ERK (B), Src (C) and STAT (D) signaling proteins in DU145 cells
The investigated tyrphostins were added at concentration equal their IC50. Statistical sig-
nificience < 0.05 in bold.
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ity in growth factor-stimulated pathway signaling, prob-
ably with participation of the same signaling proteins. 
Therefore, we checked the influence of the investigated 
tyrphostins on phosphorylation of proteins involved in 
mitogen signaling pathway.
The time course of the changes in protein phospho-
rylation, as well as the level of inhibition for all three 
inhibitors was very similar. The phosphorylation of Akt 
was decreased to about 50 % of the control value after 
3 h of incubation, regardless of the kind of the inves-
tigated tyrphostin. It returned to the control level af-
ter 24 h of treatment with these tyrphostins. Similarly, 
phosphorylation of Src decreased to about 70 % of the 
control level after the first 3 h of incubation with the 
investigated tyrphostins and returned to the control 
value after the subsequent 9 h. Also the kinetics of 
the inhibition of STAT3 phosphorylation did not dif-
fer between the investigated compounds. A comparison 
of the effect of A23, AG1024 and SU1498 on ERK 
phosphorylation was difficult to interpret because of 
the small effect of the inhibitors. However, some dif-
ferences in the inhibition activity of the investigated 
tyrphostins after the first 3 h and 6 h of incubation 
were observed.
Effect of tyrphostins AG1024, SU1498 and A23 on TGFα 
production by DU145 cells
One of the possible indirect actions of IGFs and 
VEGF on autocrine growth stimulation of DU145 
cells was their effect on TGFα production. Therefore, 
we determined the effect of AG1024 and SU1498 (in 
comparison with A23) on the level of TGFα in the 
culture medium of the investigated cells. As shown 
in Fig. 4, DU145 cells incubated with tyrphostin A23 
produced the same amount of TGFα as untreated 
cells. AG1024, a selective inhibitor of IGFIR tyrosine 
kinase, increased the concentration of the secreted 
TGFα in the conditioned medium by about 24 %. In 
contrast, treatment with SU1498 resulted in lowering 
of the production of this EGFR ligand to 74 % of the 
control value.
Effect of tyrphostins AG1024, SU1498 and A23 on 
activation of EGFR
Activation of receptor tyrosine kinases is due to their 
autophosphorylation, stimulated by specific ligand bind-
ing with the extracellular part of the receptor. The effect 
of tyrphostins AG1024, SU1498 and A23 on phosphor-
ylation of EGFR in DU145 cells (Fig. 5) was surprising. 
All the investigated inhibitors, used in respective IC50 
concentrations, decreased the phosphorylation of EGFR 
to the same degree, and following the same time course. 
The obtained results strongly suggest that inhibition 
of EGFR activation is the first (main) step in inhibition 
of mitogen signaling in DU145 cells, regardless of the 
kind of ligands (TGFα, IGFs or VEGF) and their spe-
cific receptors. 
DISCUSSION
Autocrine growth stimulation of DU145 cells by EGF/
TGFα  is well documented (Salomon et al., 1995; Seth et 
al., 1999; Blackledge, 2003). The results of earlier experi-
ments (Ferrer et al., 1999; Gennigens et al., 2006) indicated 
that DU145 cells showed also overexpression of IGFII and 
VEGF. These findings, in connection with an increased 
level of IGFRI and VEGFRs, suggested the participa-
tion of IGFRs and VEGFs in autocrine growth regula-
tion of the investigated cells. There was one in vitro study 
which showed that IGFIR antibodies inhibited DNA syn-
thesis in PC3, but not the DU145 cell lines (Kimura et al., 
1996); however, other investigators found that IGFIR an-
tibody prevents proliferation of both the prostate cell lines 
(Maloney et al., 2003). Although an association may exist 
between IGFI and prostate cancer, direct causality has not 
been established (Meinbach & Lokeshwar, 2006). Another 
question is the role of VEGFR in autocrine growth regu-
lation of prostate cells. Several investigations indicated that 
VEGF is mainly the angiogenic and chemotactic factor 
for prostate cancer cells; however, it may regulate tumor 
growth in vitro (Jackson et al., 2002). 
We have determined (Kisielewska et al., 2008) that 
blockade of  the IGFIR or VEGF2R signaling pathways 
inhibits autocrine growth and viability of DU145 cells in 
vitro. Our results indicate that both investigated tyrphostins 
(AG1024 and SU1498) at concentration ≥ 10 µM are able 
to inhibit completely DU1a 45 autocrine cell growth. 
These results suggest that the two growth factor receptors 
(IGFIR, VEGFR2) induce a common signaling route, or 
that activation of one of the investigated receptors influ-
ences the mitogenic pathway of the other. Further experi-
ments have revealed that both the investigated inhibitors 
increase the percentage of DU145 cells in G0/G1 phase of 
Figure 4. Effects of AG1024, SU1498 and A23 on synthesis and 
secretion by DU145 cells
Concentration of TGFα was assessed by ELISA after 30 h of incu-
bation of DU145 cells in DMEM/F12+ supplemented or not with 
investigated tyrphostins. *Statistical significant p < 0.05.
Figure 5. Influence of tyrphostins AG1024, SU1498 and A23 on 
EGFR phosphorylation
DU145 cells were incubated with investigated compounds (added 
at concentration equal IC50) for 3, 6, 12 and 24 h in serum-free 
medium (DMEM/F12+). Statistical significance < 0.05 in bold. 
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cell cycle, indicating that AG1024 and SU1498 arrest cell 
growth in G0/G1 phase, similarly as do known inhibitors 
of EGFR (Bonaccorsi et al., 2004; Bellezza et al., 2006).
A comparison of the IC50 values for the anti-proliferative 
and enzyme inhibitory activities (12 : 1) of AG1024 suggests 
that the true ligand for IGFIR in the case of DU145 cells 
is IGFII rather than IGFI, and supports the hypothesis of 
IGFII/IGFIR autocrine loop in this type of cancer pros-
tate cells (Figueroa et al., 1995). We confirm that DU145 
cells do not produce insulin-like growth factor I, and IGFI 
cannot be an autocrine growth factor for these cells. In 
contrast, DU145 cells produce a great amount of VEGF 
(much more than TGFα) and this protein may be the real 
autocrine growth factor of the investigated cells. Incuba-
tion of DU145 cells with AG1024 and SU1498 indicates 
a weak (about 25 % of the control) and opposing effect of 
these tyrphostins on production of TGFα, which excludes 
the possibility that IGFs and VEGF stopped the growth of 
these cells by inhibition of synthesis or secretion of TGFα.
The mitogenic pathways stimulated by growth factors 
engage several proteins, including Akt (PKB), ERK(1/2), 
Src and STAT, the activity of which is regulated by phos-
phorylation/dephosphorylation. The obtained data indicate 
that all three tyrphostins inhibit intracellular signaling path-
ways, triggered by EGFR, IGFIR and VEGFR2 receptor, 
in a similar manner. A comparison of the effect of the in-
vestigated tyrphostins points to a similarity in TGFα, IGFII 
and VEGF-stimulated pathway signaling.
Unexpectedly, all the investigated inhibitors used at their 
respective IC50 concentrations decreased phosphorylation of 
EGFR to the same extent. These results strongly suggest 
that activation of EGFR is the first (main) step in initia-
tion of mitogen signaling in DU145 cells, regardless of the 
kind of ligands (TGFα, IGFs or VEGF) and their specific 
receptors. 
The presented results show that autocrine growth of 
DU145 may be regulated by at least two additional auto-
crine loops: IGFII/IGFIR and VEGF/VEGFR2, apart 
from the well-documented TGFα/EGFR loop. Such mul-
tifactor regulation of the autocrine growth of the metastatic 
cancer cell line DU145 may explain the failure of single spe-
cific tyrosine kinase inhibitors in the therapy (monotherapy) 
of prostate cancer (Blackledge, 2003; Pu et al., 2006). A role 
for the autocrine growth loop involving tyrosine kinases 
and their receptors in tumor progression has been sug-
gested for a variety of cancers. Identifying biologically and 
physiologically important autocrine growth events may have 
important clinical consequences, also for the introduction 
of new strategies in anticancer therapies.
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